已传文件：photo/1773121782.png
The main reasons why sulfoxide drugs on the market are mostly racemates (not single configurations) are as follows:
Synthesis cost: The chiral synthesis or resolution process is complex, significantly increasing production costs;
Metabolic transformation: Some drugs (such as omeprazole) are converted into active configurations in the body through enzymatic action;
Efficacy requirements: Some racemates have two configurations that work synergistically (such as S/R-modafinil). Regulatory agencies often approve the marketing of racemates based on comprehensive benefits.
